Entry Detail



General Information

Database ID:exR0274611
RNA Name:hsa-miR-199b-5p
RNA Type:miRNA
Chromosome:chr9
Starnd:-
Coordinate:
Start Site(bp):128244783End Site(bp):128244805
External Links:hsa-miR-199b-5p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE22981
Description:Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer
Experimental Design:Cancer vs Control
Case Disease Type:Breast Cancer
Case Disease SubType:Early satge breast cancer
Case Sample:Breast Cancer
Control Sample:Control
Number of Case:20
Number of Control:20
Number of Samples:40





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
ALDH3B2
chr11
67662160
67681224
-
ATP9A
chr20
51596514
51768390
-
CHD2
chr15
92900189
93027996
+
COL4A2
chr13
110305812
110513209
+
COX6A1
chr12
120438090
120440737
+
FAM222B
chr17
28755978
28855232
-
FOSL2
chr2
28392448
28417317
+
HMGCS1
chr5
43287470
43313512
-
KRT80
chr12
52168996
52192014
-
MYRF
chr11
61752642
61788518
+
NFE2L1
chr17
48048329
48061545
+
SLC7A5
chr16
87830023
87869507
-
WNT5A
chr3
55465715
55490539
-
XPO6
chr16
28097979
28211920
-
ZMIZ1
chr10
79068966
79316528
+
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0000591
chr15
41961025
41962156
+
hsa_circ_0001005
chr2
53921020
53978078
-
hsa_circ_0000892
chr19
11941431
12014514
+
hsa_circ_0000931
chr19
38226804
38231095
-
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC004951.4
chr7
43951910
44019151
-
AC095055.1
chr4
151139991
151141103
+
BX284668.2
chr1
16870945
16883659
+
LINC01783
chr1
16533886
16536172
-
POLR2J4
chr7
43940895
44019175
-
SNHG12
chr1
28578538
28583132
-
TMPO-AS1
chr12
98512973
98516422
-
Display:



Experiment Detail

GEO ID:GSE22981
Sample Source:Blood
Source Fraction:Plasma
Platform:GPL8179
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:801
Sample treatment protocol:NA
RNA Extract protocol:Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications.
RNA library preparation protocol:Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).



Reference

PMID:21060830
Title:A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer
Author:Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer.
Journal:PLoS One. 2010 Oct 29;5(10):e13735.
Description:The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.